Clinical Trials Browser

Phase 2 × bavituximab × 30 days × Clear all

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2 Active not recruiting

7 enrolled 11 charts

Carcinoma, Squamous Cell